Avandia to Alogliptin: A time line of recent FDA actions on diabetes drugs
Diabetes drug alogliptin fell short of U.S. Food and Drug Administration approval on Wednesday, dealing a blow to the hopes of Takeda Pharmaceutical (TYO:4502) and its partner, Furiex Pharmaceuticals (NASDAQ:FURX). The complete response letter means Takeda will need to come up with more data if it wants to try again for FDA approval on its […]